Cargando…
phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints
Traditional dose-finding designs are substantially inefficient for targeted agents and cancer immunotherapies by failing to incorporate efficacy signals, mild and moderate adverse events, and late, cumulative toxicities. However, the lack of user-friendly software is a barrier to the practical use o...
Autores principales: | Yin, Jun, Du, Yu, Qin, Rui, Shen, Shihao, Mandrekar, Sumithra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412295/ https://www.ncbi.nlm.nih.gov/pubmed/34473708 http://dx.doi.org/10.1371/journal.pone.0256391 |
Ejemplares similares
-
Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities
por: Ezzalfani, Monia, et al.
Publicado: (2013) -
Paternal mitochondria from an rmd-2, rmd-3, rmd-6 triple mutant are properly positioned in the C. elegans zygote
por: Juanico, Iris Y, et al.
Publicado: (2021) -
Introducing RMD Open
por: Cutolo, Maurizio, et al.
Publicado: (2015) -
Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies
por: Yin, Jun, et al.
Publicado: (2016) -
Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
por: Yuan, Jiacheng, et al.
Publicado: (2018)